Stockreport

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

BeOne Medicines Ltd. - American Depositary Shares  (ONC) 
PDF New data from two pivotal TEVIMBRA studies – RATIONALE-307 and -312 – reinforce the PD-1 inhibitor’s proven clinical benefit in both NSCLC and ES-SCLCEarly data from inv [Read more]